We have an updated report [Version - 2023] available. Kindly sign up to get the sample of the report.

NEUROFIBROMATOSIS TREATMENT DRUGS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2020 to 2027)

Neurofibromatosis Treatment Drugs Market, by Disease Type (Neurofibromatosis 1 (NF1) and Neurofibromatosis 2 (NF2), and Schwannomatosis), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Published In: 21 Sep, 2020
Code: CMI4188
Pages: 166
Formats: Excel and PDF
Industry: Pharmaceutical

Neurofibromatosis is a genetic disorder of the nervous system. It mainly affects growth of nerve cells. It is characterized by the growth of tumors on nerves. Neurofibromatosis is considered as a hereditary disease which mainly occurs in children or it can happen due to mutation (change) of genes. Usually the Neurofibromatosis tumors are benign, but sometimes they can become cancerous. There are three types of neurofibromatosis: Type 1 (NF1), Type 2 (NF2), and Schwannomatosis. All three types show varied symptoms.

Market Dynamics

The increasing focus of pharma and biotech companies on the research and development of novel treatment drugs for neurofibromatosis is expected to drive the neurofibromatosis treatment drugs market growth during the forecast period. For instance, on July 8, 2020, Nobelpharma initiated phase 3 clinical trial study to evaluate the safety and efficacy of long-term treatment with NPC-12G gel for patients with neurofibromatosis type I. The study is estimated to complete in April 30, 2022.

Key features of the study:

This report provides in-depth analysis of the global neurofibromatosis treatment drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global neurofibromatosis treatment drugs market based on the following parameters – company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key company covered as a part of this study includes AstraZeneca
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future drug launches, drug class up-gradation, market expansion, and marketing tactics
The global neurofibromatosis treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neurofibromatosis treatment drugs market.

Detailed Segmentation:

Global Neurofibromatosis treatment drugs market, By Disease Type:
- Neurofibromatosis 1 (NF1)
- Neurofibromatosis 2 (NF2)
- Schwannomatosis
Global Neurofibromatosis treatment drugs market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Neurofibromatosis treatment drugs market, By Region:
- North America
  - By Disease Type:
    - Neurofibromatosis 1 (NF1)
    - Neurofibromatosis 2 (NF2)
    - Schwannomatosis
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country:
    - U.S.
    - Canada
- Latin America
  - By Disease Type:
    - Neurofibromatosis 1 (NF1)
    - Neurofibromatosis 2 (NF2)
    - Schwannomatosis
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country:
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - By Disease Type:
    - Neurofibromatosis 1 (NF1)
    - Neurofibromatosis 2 (NF2)
    - Schwannomatosis
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country:
    - Germany
    - U.K.
    - France
    - Italy
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - By Disease Type:
    - Neurofibromatosis 1 (NF1)
    - Neurofibromatosis 2 (NF2)
    - Schwannomatosis
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country:
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - By Disease Type:
    - Neurofibromatosis 1 (NF1)
    - Neurofibromatosis 2 (NF2)
    - Schwannomatosis
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country/Region:
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - By Disease Type:
    - Neurofibromatosis 1 (NF1)
    - Neurofibromatosis 2 (NF2)
    - Schwannomatosis
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country/Region:
    - South Africa
    - Central Africa
    - North Africa
Company Profile
- AstraZeneca *
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Key Highlights
  - Market Strategies

“*” marked represents similar segmentation in other categories in the respective section.

Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
Market Purview
- Report Description
  - Market Definition and Scope
- Executive Summary
  - Market Snippet, By Disease Type
  - Market Snippet, By Distribution Channel
  - Market Snippet, By Region
  - Coherent Opportunity Map (COM)
Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
  - Drivers
  - Restraints
  - Impact Analysis
- Market Opportunities
- Collaborations and Acquisition
- Regulatory Scenario
Global Neurofibromatosis Treatment Drugs Market, Impact of COVID-19 Pandemic
- During COVID-19 Impact
- Post COVID-19 Impact
- Government Initiatives
- Overall Impact On Healthcare Industry
Global Neurofibromatosis Treatment Drugs Market, By

Disease Type, 2016-2027 (US$ Mn)
- Introduction
  - Market Share Analysis, 2020 and 2027 (%)
  - Y-o-Y Growth Analysis, 2017–2027
  - Segment Trends
    - Neurofibromatosis 1 (NF1)
      - Introduction
      - Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
    - Neurofibromatosis 2 (NF2)
      - Introduction
      - Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
    - Schwannomatosis
      - Introduction
      - Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
Global Neurofibromatosis Treatment Drugs Market, By Distribution Channel, 2016 – 2027, (US$ Mn)
- Introduction
  - Market Share Analysis, 2020 and 2027 (%)
  - Y-o-Y Growth Analysis, 2017– 2027
  - Segment Trends
    - Hospital Pharmacies
      - Introduction
      - Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
    - Retail Pharmacies
      - Introduction
      - Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
    - Online Pharmacies
      - Introduction
      - Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
Global Neurofibromatosis Treatment Drugs Market, By Region, 2016–2027 (US$ Mn)
- Introduction
  - Market Share Analysis, By Country, 2020 and 2027 (%)
  - Y-o-Y Growth Analysis, For Countries, 2017–2027
- North America
  - Introduction
  - Market Size and Forecast, By Disease Type, 2016–2027 (US$ Mn)
  - Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
  - Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
    - U.S.
    - Canada
- Latin America
  - Introduction
  - Market Size and Forecast, By Disease Type, 2016–2027 (US$ Mn)
  - Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
  - Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - Introduction
  - Market Size and Forecast, By Disease Type, 2016–2027 (US$ Mn)
  - Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
  - Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
    - Germany
    - U.K.
    - France
    - Italy
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - Introduction
  - Market Size and Forecast, By Disease Type, 2016–2027 (US$ Mn)
  - Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
  - Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - Introduction
  - Market Size and Forecast, By Disease Type, 2016–2027 (US$ Mn)
  - Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
  - Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - Introduction
  - Market Size and Forecast, By Disease Type, 2016–2027 (US$ Mn)
  - Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
  - Market Size and Forecast, By Country/Region, 2016–2027 (US$ Mn)
    - South Africa
    - Central Africa
    - North Africa
Competitive Landscape
- Company Profiles
  - AstraZeneca Plc.*
    - Company Overview
    - Disease Type Portfolio
    - Financial Overview
    - Key Highlights
    - Market Strategies

*Browse 22 market data tables and 24 figures on "Global Neurofibromatosis Treatment Drugs Market– Global forecast to 2027”.

Limited Time Offer - Buy Now

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now